Q1 Earnings Forecast for Medpace Issued By Leerink Partnrs

Medpace Holdings, Inc. (NASDAQ:MEDP) – Analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Medpace in a research note issued on Monday, March 24th. Leerink Partnrs analyst M. Cherny expects that the company will earn $3.03 per share for the quarter. Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Medpace’s current full-year earnings is $12.29 per share. Leerink Partnrs also issued estimates for Medpace’s Q2 2025 earnings at $2.96 EPS, Q3 2025 earnings at $2.92 EPS, Q4 2025 earnings at $3.16 EPS, FY2025 earnings at $12.07 EPS, FY2026 earnings at $12.76 EPS, FY2027 earnings at $13.90 EPS and FY2028 earnings at $15.81 EPS.

Several other brokerages also recently commented on MEDP. Robert W. Baird boosted their target price on shares of Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research note on Monday, January 27th. Leerink Partners began coverage on shares of Medpace in a research report on Monday. They issued a “market perform” rating and a $330.00 price target on the stock. Nine research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $376.30.

Medpace Price Performance

Shares of MEDP stock opened at $316.61 on Wednesday. The stock’s fifty day simple moving average is $336.40 and its 200 day simple moving average is $339.26. Medpace has a one year low of $302.01 and a one year high of $459.77. The firm has a market cap of $9.65 billion, a price-to-earnings ratio of 25.07, a P/E/G ratio of 3.81 and a beta of 1.47.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%.

Institutional Investors Weigh In On Medpace

Institutional investors and hedge funds have recently made changes to their positions in the company. Pallas Capital Advisors LLC increased its position in Medpace by 179.7% in the fourth quarter. Pallas Capital Advisors LLC now owns 3,270 shares of the company’s stock worth $1,086,000 after purchasing an additional 2,101 shares during the period. Barclays PLC boosted its stake in shares of Medpace by 71.9% in the 3rd quarter. Barclays PLC now owns 19,781 shares of the company’s stock valued at $6,603,000 after purchasing an additional 8,275 shares during the last quarter. Sanctuary Advisors LLC grew its position in shares of Medpace by 20.5% during the 4th quarter. Sanctuary Advisors LLC now owns 4,964 shares of the company’s stock worth $1,738,000 after buying an additional 844 shares during the period. Janus Henderson Group PLC raised its stake in shares of Medpace by 10.0% during the third quarter. Janus Henderson Group PLC now owns 44,118 shares of the company’s stock worth $14,722,000 after buying an additional 4,023 shares during the last quarter. Finally, SYM FINANCIAL Corp acquired a new position in Medpace in the fourth quarter valued at approximately $320,000. Institutional investors own 77.98% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.